After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: …
Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
